SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

BIOA

BioAge Labs, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed11d 5h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

QUELL-CV topline data in Q4 2026 is the next major catalyst; a positive readout on hsCRP reduction and biomarker profile could support dose selection and de-risk the program. Monitor cash burn trajectory as R&D spending escalates with two Phase 2 trials.

DirectionNeutral
Confidencehigh
Horizonweeks

BGE-102

▲ Bullish Named in this press release
Impact
Phase
Phase 2
Time to market
At least 3-5 years away. BGE-102 is in Phase 2; even with positive data, Phase 3 trials and FDA review would take several years. The QUELL-DME trial results are not expected until H2 2027.
Next catalyst
None dated

What to watchThe QUELL-CV Phase 2 topline data, expected in Q4 2026 (any day now through December), is the single most important catalyst. Positive data showing a clear dose-response on hsCRP and cardiometabolic biomarkers would validate BGE-102's best-in-class profile and likely drive a significant stock re-rating given the current depressed valuation. Negative or equivocal data would compound the sector skepticism from Novo Nordisk's failure and could pressure the stock further. QUELL-DME data in H2 2027 is a secondary catalyst.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$5.34
T+0 close · Nov 5, 2026 · via day close
Latest settled
+3.93%
T+5 · $5.55
Vs SPY
+1.34%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $5.34entry
  2. T+1 · 8d ago +6.55%α +4.19% · $5.69
  3. T+5 · 4d ago +3.93%α +1.34% · $5.55
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioAge reported Q3 2026 net loss of $33.5M ($0.73/share), wider than the $20.2M loss a year ago, as R&D spending surged to $30.2M to support Phase 2 trials of BGE-102. The company dosed the first patient in the QUELL-DME trial and completed enrollment in QUELL-CV, with topline data from QUELL-CV expected in Q4 2026. Cash of $352.3M is expected to fund operations through 2029.

Key Financial Metrics

EPS
−$0.73
Revenue
$298.0K
est $1.5M · -80.1% · -85.5% YoY

Key Facts

  • Net loss of $33.5M ($0.73/share) vs $20.2M ($0.56/share) in Q3 2025
  • Collaboration revenue $0.3M, down from $2.1M a year ago
  • R&D expenses $30.2M, up 63% from $18.5M, driven by BGE-102 clinical costs
  • Cash, cash equivalents and marketable securities $352.3M as of Sep 30, 2026
  • First participant dosed in QUELL-DME Phase 2 trial for diabetic macular edema; topline results H2 2027
  • QUELL-CV Phase 2 trial fully enrolled; topline data expected Q4 2026
  • APJ agonist program on track for IND filing by year-end 2026
  • Collaboration with Novartis amended in Sep 2026, adding $0.9M research funding

Financial Impact

Net loss widened by $13.3M YoY; cash burn rate increased; cash runway through 2029

net lossR&D expensescash position

Risk Factors

  • QUELL-CV or QUELL-DME trial results may not meet primary endpoints
  • Rising R&D costs could accelerate cash burn if timelines extend
  • Collaboration revenue decline reflects lumpy nature of partnership milestones

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3397158

Track record

11 reports on BIOA

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +13.00% at T+60 after the Apr 21, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $5.50 Now $5.22 −5.09% settles Nov 23
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Viewing Entry $5.34 to $5.55 Now $5.22 −2.25% ▲ +3.93% +1.34% vs SPY
  4. Jun 16, 202621w ago Press Release Neutral 3/10 Entry $20.49 to $22.32 Now $5.22 −74.52% ▲ +8.93% +11.16% vs SPY
  5. May 8, 202627w ago 8-K Bullish 7/10 Entry $17.99 to $18.72 Now $5.22 −70.98% ▲ +4.03% +2.57% vs SPY
  6. Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $18.36 to $17.14 Now $5.22 −71.57% ▼ −6.64% −6.70% vs SPY
  7. Apr 21, 202629w ago Press Release Bullish 8/10 Entry $19.61 to $17.44 Now $5.22 −73.38% ▼ −11.07% −12.15% vs SPY
  8. Apr 1, 202632w ago 144 Neutral 3/10 Entry $17.73 to $17.79 Now $5.22 −70.56% ▲ +0.34% −3.43% vs SPY
  9. Mar 24, 202633w ago Press Release Mixed 6/10 Entry $16.11 to $17.49 Now $5.22 −67.60% ▲ +8.57% +8.99% vs SPY
  10. Mar 2, 202637w ago Court Ruling Bullish 7/10 Entry $20.46 to $20.97 Now $5.22 −74.49% ▲ +2.49% +2.96% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Wed (11h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026